[Selective COX-2 inhibitor-associated colitis: two case reports].
Non-steroidal anti-inflammatory drugs (NSAIDs) reduce prostaglandin synthesis by inhibiting cyclo-oxygenase 1 (COX-1) and/or cyclo-oxygenase 2 (COX-2). Different groups of NSAIDs, defined by their action on either COX-1 or COX-2, have been developed. Whether intestinal toxicity of preferential or selective COX-2 inhibitors is reduced compared with that of standard NSAIDs is controversial. We report the cases of two patients with self-limited colitis induced by preferential COX-2. We discuss the mechanisms of intestinal toxic effects of COX-2 preferential inhibitors from endoscopic and histological features of colitis.
d'Halluin
Pierre-Nicolas
PN
Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, 35033 Rennes.
Turlin
Bruno
B
Polard
Elisabeth
E
Dinasquet
Michel
M
Pagenault
Maël
M
Rioux
Nathalie
N
Gosselin
Michel
M
Bretagne
Jean-François
JF
Heresbach
Denis
D
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D003092:Colitis / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000077239:Meloxicam; D008875:Middle Aged; D013449:Sulfonamides / Q000009:adverse effects*; D013843:Thiazines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D013449:Sulfonamides; D013843:Thiazines; D013844:Thiazoles; C012655:nimesulide; D000077239:Meloxicam